Skip to main content
Search
Search
Philippines | en
Choose Location
Americas
Asia Pacific
Europe
International
Middle East & Africa
Argentina |
Español
Brazil |
Português
Canada |
English
Canada |
Français
Central America |
Español
Colombia |
Español
Mexico |
Español
United States |
English
Australia |
English
Bangladesh |
English
Hong Kong S.A.R. |
繁體中文
India |
English
Indonesia |
English
Japan |
日本語
Korea |
한국어
Mainland China |
中文
Malaysia |
English
Pakistan |
English
Philippines |
English
Singapore |
English
Taiwan |
繁體中文
Thailand |
ภาษาไทย
Austria |
Deutsch
Belgium |
Français
Belgium |
Nederlands
Bulgaria |
Български
Czech Republic |
Česky
Czech Republic |
English
Denmark |
Dansk
Estonia |
Eesti
Finland |
Suomalainen
France |
Français
Germany |
Deutsch
Greece |
Ελληνικά
Hungary |
Magyar
Ireland |
English
Italy |
Italiano
Latvia |
Latvian
Lithuania |
Lithuanian
Netherlands |
Nederlands
Norway |
Norsk
Poland |
Polski
Portugal |
Português
Romania |
Română
Russia |
Русский
Serbia |
Srpski
Slovakia |
Slovensky
Slovenia |
Slovenščina
Slovenia |
English
Spain |
Español
Sweden |
Svenska
Switzerland |
Deutsch
Switzerland |
Français
Türkiye |
Türkçe
United Kingdom |
English
Global |
English
Novartis Foundation |
English
Egypt |
English
Israel |
עברית
Saudi Arabia |
العربية
South Africa |
English
Philippines
Choose Location
asia-pacific
Americas
Asia Pacific
Europe
International
Middle East & Africa
Argentina |
Español
Australia |
English
Austria |
Deutsch
Bangladesh |
English
Belgium |
Français
Belgium |
Nederlands
Brazil |
Português
Bulgaria |
Български
Canada |
English
Canada |
Français
Central America |
Español
Colombia |
Español
Czech Republic |
Česky
Czech Republic |
English
Denmark |
Dansk
Egypt |
English
Estonia |
Eesti
Finland |
Suomalainen
France |
Français
Germany |
Deutsch
Greece |
Ελληνικά
Hong Kong S.A.R. |
繁體中文
Hungary |
Magyar
India |
English
Indonesia |
English
Ireland |
English
Israel |
עברית
Italy |
Italiano
Japan |
日本語
Korea |
한국어
Latvia |
Latvian
Lithuania |
Lithuanian
Mainland China |
中文
Malaysia |
English
Mexico |
Español
Netherlands |
Nederlands
Norway |
Norsk
Global |
English
Novartis Foundation |
English
Pakistan |
English
Philippines |
English
Poland |
Polski
Portugal |
Português
Romania |
Română
Russia |
Русский
Saudi Arabia |
العربية
Serbia |
Srpski
Singapore |
English
Slovakia |
Slovensky
Slovenia |
Slovenščina
Slovenia |
English
South Africa |
English
Spain |
Español
Sweden |
Svenska
Switzerland |
Deutsch
Switzerland |
Français
Taiwan |
繁體中文
Thailand |
ภาษาไทย
Türkiye |
Türkçe
United Kingdom |
English
United States |
English
Menu
About
Novartis in Philippines
Strategy
Diversity and Inclusion
People and Culture
Products
Country Leadership Team
Contact
About
Patients and Caregivers
Novartis Commitment to Patients and Caregivers
Diseases
Patient resources
Products
Adverse Event Reporting
Patients and Caregivers
Healthcare Professionals
Healthcare professional country resource
Products
Novartis Pipeline
Adverse Event Reporting
Novartis Clinical Trials
Healthcare Professionals
ESG
Financial Transparency for Philippines
Ethical Behavior
Code of Ethics
SpeakUp
Ethics, Risk and Compliance
Access
Environmental Sustainability
Global Health
ESG
News
News Archive
Stories
Contacts
News
Careers
Career Search
Meet the teams
Personal Growth
Early Talent
How We Work
Well-being
Diversity and Inclusion
Career Programs
Awards and Recognition
Careers
Coronavirus
Coronavirus
Home
Unblocked Heart Health
Tags Archive Navigation
Tags Archive Navigation
All
Careers
Feature News
In the News
Media Releases
Story
icon
List View
Story
Nov 13, 2023
Lowering LDL-C is crucial after a heart attack or percutaneous coronary intervention
Pagination
